Vevye: A New Cyclosporine Solution for Dry Eye Disease
XTalks
JUNE 14, 2023
Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. In addition, Sylentis, a biotech company specializing in ophthalmic drugs and RNA interference (RNAi) technology, initiated a Phase III study in 2021.
Let's personalize your content